European Equities Traded in the US as American Depositary Receipts Edge Lower in Monday Trading

MT Newswires Live
Yesterday

European equities traded in the US as American depositary receipts opened the week slightly lower late Monday morning, declining 0.12% to 1,952.52 on the S&P Europe Select ADR Index.

From continental Europe, the gainers were led by pharmaceutical company Ascendis Pharma (ASND) and 3D printer company Materialise (MTLS), which rose 6.6% and 2.8%, respectively. They were followed by petroleum refiner Equinor (EQNR) and oil and gas company Eni (E), which were up 2.7% and 2.6%, respectively.

The decliners from continental Europe were led by internet browser company Opera (OPRA) and biotech firm Evaxion (EVAX), which fell 1.9% and 1.7% respectively. They were followed by telecommunications company Nokia (NOK) and accommodations booking site trivago (TRVG), which were down 1.3% and 1.2% respectively.

The gainers from the UK were led by biopharmaceutical company Mereo BioPharma Group (MREO) and software firm Endava (DAVA), which advanced 14% and 1.9% respectively. They were followed by oil and gas companies BP (BP) and Shell (SHEL), which increased 1.3% and 0.9% respectively.

The decliners from the UK and Ireland were led by biopharmaceutical companies NuCana (NCNA) and Biodexa Pharmaceuticals (BDRX), which dropped 16% and 5.9% respectively. They were followed by biopharmaceutical company Akari Therapeutics (AKTX) and pharmaceutical company Silence Therapeutics (SLN), which increased 3.7% and 2.3% respectively.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10